Danish biotech fledgling to present research results at biotech conference  

Danish biotech fledgling Enkam Pharmaceuticals will present its research result on the treatment of Alzheimer's disease at Biotech Forum, and aims to sell its lead compound

Danish biotech fledgling Enkam Pharmaceuticals has been invited to present its research results alongside Wyeth and Eli Lilly in the CNS Therapeutics and Alzheimer's disease session at Biotech Forum, an international biotech conference currently being held in Copenhagen. Morten Albrechtsen, managing director of Enkam Pharmaceuticals comments:

"So far we have been on the observation list among those who are engaged in Alzheimer's disease, but we see it as an approval of our technology that we have been invited to present our results. It is becoming accepted that we have a potential way of treating the disease."

Enkam has recently tested its lead compound FGL for the treatment of Alzheimer's disease in a phase I clinical study, where it was demonstrated to be well tolerated. Enkam Pharmaceuticals is preparing the compound for the next stage of testing and plans to sell FGL to a large pharmaceutical company:

"Alzheimer's disease is highly complex and requires long and expensive studies. So either we can choose to take small steps on venture capital or go to a large pharmaceutical group and sell it to them. We are aiming for the latter model because it will lead to more effective development. Our assessment is that we will get the best value out of selling it now," Albrechtsen says.

The news was reported by financial daily newspaper Børsen.

Link > Enkam Pharmaceuticals 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×